{"meshTags":["Antineoplastic Agents","Benzamides","Combined Modality Therapy","Digestive System Surgical Procedures","Follow-Up Studies","Gastrectomy","Gastrointestinal Neoplasms","Gastrointestinal Stromal Tumors","Humans","Imatinib Mesylate","Italy","Neoadjuvant Therapy","Neoplasm Recurrence, Local","Omentum","Piperazines","Protein Kinase Inhibitors","Pyrimidines","Retrospective Studies"],"meshMinor":["Antineoplastic Agents","Benzamides","Combined Modality Therapy","Digestive System Surgical Procedures","Follow-Up Studies","Gastrectomy","Gastrointestinal Neoplasms","Gastrointestinal Stromal Tumors","Humans","Imatinib Mesylate","Italy","Neoadjuvant Therapy","Neoplasm Recurrence, Local","Omentum","Piperazines","Protein Kinase Inhibitors","Pyrimidines","Retrospective Studies"],"genes":["tyrosine kinase"],"publicationTypes":["English Abstract","Journal Article","Review"],"abstract":"Gastrointestinal stromal tumors (GIST) are generally found in the stomach or small intestine and less commonly in the colon and rectum. Complete surgical remove remains the best current therapy. In the treatment of advanced/metastatic GIST is available imatinib, a selective tyrosine kinase inhibitor. In our experience, 12 patients observed between 2000 and 2007 and affected by GIST underwent surgery, in one case associated to treatment with imatinib.","title":"[GIST: our experience].","pubmedId":"19272232"}